Tarsus Pharmaceuticals has appointed David E. I. Pyott, former Chairman and CEO of Allergan and current director at several ...

IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will ...

IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global ...

Tarsus Pharmaceuticals, Inc. (TARS) is expected to deliver a year-over-year increase in earnings on higher revenues when it ...

The consensus estimate for Q4 2025 revenue is $0.14 billion, and the earnings are expected to come in at -$0.11 per share. The full year 2025's revenue is expected to be $0.44 billion, and the ...

How do you market a drug for a disease that will make most people squirm? Well, Tarsus isn’t shying away from the topic and is going all out on its new campaign aimed at a condition caused by a skin ...

As the first treatment cleared by the FDA for Demodex blepharitis, an eye disease estimated to affect 25 million people in the U.S. alone, Tarsus Pharmaceuticals’ Xdemvy is pitting its might against ...

As part of its latest eye care campaign, Tarsus Pharmaceuticals has a simple message for patients with demodex blepharitis: Don’t Freak Out, Get Checked Out. Since May is Health Vision Month, the ...

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company’s ...

Cherry Bekaert has acquired accounting and advisory firm Tarsus to expand outsourced accounting, real-time financial reporting and strategic chief financial officer services for clients in government ...